Rong Wang, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is a cancer epidemiologist who studies the health outcomes and etiology of different types of cancers, especially hematopoietic malignancies. She is interested in the pattern of care, treatment and cost in older adults. She is also working on traffic exposure and genetic characteristics on the risk of cancer.
Last Updated on May 09, 2025.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimary
Other Departments & Organizations
- All Institutions
- Chronic Disease Epidemiology
- COPPER Center
- Yale School of Public Health
Education & Training
- PhD
- Yale University (2008)
Research
Copy Link
Overview
Medical Research Interests
Biostatistics; Chronic Disease; Epidemiology; Health Care; Neoplasms
Public Health Interests
Maternal & Child Health; Environmental Health; Cancer
ORCID
0000-0002-2169-4174
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rong Wang's published research.
Publications Timeline
A big-picture view of Rong Wang's research output by year.
Research Interests
Research topics Rong Wang is interested in exploring.
Xiaomei Ma, PhD
Nikolai Podoltsev, MD, PhD
Amer Zeidan, MBBS, MD
Scott Huntington, MD, MPH, MSc
Natalia Neparidze, MD
Cary P Gross, MD
131Publications
2,205Citations
Neoplasms
Chronic Disease
Publications
2026
Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States.
Leapman M, Wang R, Sprenkle P, Kim I, Dinan M, Gross C, Ma X. Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States. Journal Of Clinical Oncology 2026, 44: 350-350. DOI: 10.1200/jco.2026.44.7_suppl.350.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerIntermediate-risk diseaseProstate cancerActive surveillanceAssociated with lower oddsClinical dataGC scoresGenomic classifierManagement of localized prostate cancerLow-risk diseaseLocalized prostate cancerIntermediate-risk groupLower oddsGenomic classifier scoresProstate cancer diagnosisLow-risk groupClinical risk groupsMultivariate logistic regressionPopulation-based cohortPopulation-based linkageRisk diseaseInitial treatmentPrognostic informationInitial managementPathological covariatesOverestimation of multiple myeloma survival from cancer registry data
Huber J, Wang M, Wang R, Schoen M, Colditz G, Wang S, Chang S. Overestimation of multiple myeloma survival from cancer registry data. Journal Of The National Cancer Institute 2026, djag028. PMID: 41652897, PMCID: PMC12967285, DOI: 10.1093/jnci/djag028.Peer-Reviewed Original ResearchAltmetricConceptsSymptomatic MMMultiple myelomaFive-year relative survival estimatesSurvival statisticsCancer registry dataRelative survival estimatesMM managementPremalignant conditionSurveillance, EpidemiologyMultiple myeloma survivalRegistry dataMedian survivalMM survivalMyeloma survivalSEERPopulation levelSurvival estimatesSurvivalMyelomaMonthsStatisticallyInclusionEpidemiologyPatientsSmoldering multiple myeloma in the United States: a population-based analysis
Wang S, Wang R, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff A, Chang S. Smoldering multiple myeloma in the United States: a population-based analysis. Blood Advances 2026, 10: 661-664. PMID: 41213002, PMCID: PMC12870838, DOI: 10.1182/bloodadvances.2025017817.Peer-Reviewed Original ResearchAltmetricResidential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California
Clark C, Johnson N, Wang R, Stewart E, Spector L, Wiemels J, Metayer C, Deziel N, Ma X. Residential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California. Environmental Health 2026, 25: 12. PMID: 41535920, PMCID: PMC12888232, DOI: 10.1186/s12940-025-01259-3.Peer-Reviewed Original ResearchAltmetricConceptsSarcoma riskControls frequency-matched to casesHispanic childrenFrequency-matched to casesOdds ratioCalifornia Cancer RegistryClustering of cancerConfidence intervalsPediatric cancer riskNon-Hispanic childrenMultivariate logistic regressionBirth addressCancer RegistryHealth outcomesEwing sarcomaNon-HispanicCancer riskChildhood cancerResidential proximityBirth yearUnexposed childrenLogistic regressionMethodsThis studyExposure disparitiesDiagnosis of Ewing's sarcomaTrends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
Wang R, Davidoff A, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Chang S, Wang S. Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022. American Journal Of Hematology 2026, 101: 923-925. PMID: 41528052, PMCID: PMC12912868, DOI: 10.1002/ajh.70202.Peer-Reviewed Original ResearchAltmetric
2025
Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States
Stempel J, Wang R, Shallis R, Mendez L, Bewersdorf J, Stahl M, Zeidan A, Ma X, Podoltsev N. Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States. Blood 2025, 146: 6392-6392. DOI: 10.1182/blood-2025-6392.Peer-Reviewed Original ResearchAltmetricConceptsHistory of thrombosisDiagnosis of DMMetformin non-usersMyeloproliferative neoplasmsMetformin usersThrombotic eventsThrombotic riskPolycythemia veraMetformin useEssential thrombocythemiaOlder ptsSevere DMDiabetes mellitusImpact of metforminNo significant associationDM severityFollow-upPhiladelphia chromosome negative myeloproliferative neoplasmsPre-existing cardiovascular risk factorsHistory of thrombotic eventsNon-usersIncidence rate of thrombosisIncidence of thrombotic eventsDevelopment of myeloproliferative neoplasmsIncidence rateTreatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)
Wang R, Stempel J, Shallis R, Bewersdorf J, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA). Blood 2025, 146: 6393-6393. DOI: 10.1182/blood-2025-6393.Peer-Reviewed Original ResearchConceptsMedian time to initiationChronic myeloid leukemiaTime to initiationMonths of diagnosisRetrospective cohort studyTreatment initiationAssociated with higher likelihoodTKI therapyOlder ptsCML diagnosisFollow-upOlder patientsFirst-generation TKI imatinibChronic myeloid leukemia diagnosisEnd Results Medicare-linked databaseMultivariate Cox proportional hazards modelLow-income subsidySecond-generation TKIsMedicare-linked databaseAge of diagnosisCox proportional hazards modelsPre-GProportional hazards modelGeneric imatinibImatinib usersEvaluation of disparities in the incidence, presentation, and treatment of pediatric differentiated thyroid cancer in the United States (2000–2022)
Ning X, Wang R, Ogilvie J, Dinauer C, Ma X, Deziel N. Evaluation of disparities in the incidence, presentation, and treatment of pediatric differentiated thyroid cancer in the United States (2000–2022). PLOS ONE 2025, 20: e0333401. PMID: 41100458, PMCID: PMC12530529, DOI: 10.1371/journal.pone.0333401.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsNon-Hispanic Asian/Pacific IslanderNon-Hispanic white patientsAnnual percent changeAsian/Pacific IslanderSocioeconomic statusNational childhood cancer registryChildhood Cancer RegistryWhite patientsJoinpoint regression analysisNon-Hispanic blacksPediatric thyroid cancer incidenceThyroid cancer incidenceCancer management guidelinesManagement guidelinesEvaluation of disparitiesNon-white childrenThyroid cancer management guidelinesCancer RegistryCancer incidenceTumor sizeThyroid cancerCancer presentationHispanic childrenTimely accessPercent changeChanges in Colorectal Cancer Screening Modalities Among Insured Individuals
Siddique S, Wang R, May F, Baum L, Gross C, Ma X. Changes in Colorectal Cancer Screening Modalities Among Insured Individuals. JAMA Network Open 2025, 8: e2538578. PMID: 41118161, PMCID: PMC12541536, DOI: 10.1001/jamanetworkopen.2025.38578.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFecal immunochemical testStool DNA testColorectal cancer screening modalitiesSocioeconomic statusScreening modalitiesMetropolitan area residentsRetrospective cohort studyDynamic cohortArea-level socioeconomic statusColorectal cancerMarkers of socioeconomic statusCohort studyTest useArea residentsAverage-risk individualsCancer screening modalitiesDNA testingImmunochemical testCOVID-19 pandemicSociodemographic groupsMain OutcomesClaims dataColonoscopyCOVID-19ResidentsGastric Adenocarcinoma in the United States: The Toll of Late Diagnosis and Racial and Geographic Disparities
Hyun C, Wang R, Kim Y, Hong S, Shin J, Sundar R, Kunz P. Gastric Adenocarcinoma in the United States: The Toll of Late Diagnosis and Racial and Geographic Disparities. JCO Oncology Advances 2025 DOI: 10.1200/oa-25-00063.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGastric adenocarcinomaPoor survivalHazard ratioGastric cancerMedian survivalGeographic disparitiesRacial disparitiesDistant stageNon-Hispanic black patientsSurvival rateNon-Hispanic AsiansTargeted prevention strategiesEarly detection effortsHigh-risk populationTumor locationSurvival outcomesLate diagnosisPrevention strategiesElevated riskUnited StatesBlack patientsDetection programGA incidenceGA casesDisparities
Academic Achievements & Community Involvement
Copy Link
News
Copy Link
News
- October 28, 2025Source: Yale News
Study Reveals Demographic Disparities in Uptake of Colorectal Cancer Screenings
- October 27, 2025
New Study Highlights Need for Coordinated Approach to Stomach Cancer Screening and Prevention
- June 03, 2025Source: Yale News
Insights & Outcomes: Star Music, Kavli Kudos, and Summertime Heart Risks
- May 14, 2025
Faculty Research Awards Showcase YSPH Strengths in Science
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Locations
1 Church Street
Academic Office
Ste 200, Rm 225
New Haven, CT 06510